Switching from infliximab to biosimilar in inflammatory bowel disease

QR kód

Switching from infliximab to biosimilar in inflammatory bowel disease

Biological therapy has revolutionized the treatment of inflammatory bowel disease (IBD). After the expiration of patents for biological innovator products, development of biosimilars increased. CT-P13 was the first biosimilar approved for the same indications as the reference product; however, the a...

Teljes leírás

Elmentve itt :

Bibliográfiai részletek
Szerzők:	Milassin Ágnes Fábián Anna Molnár Tamás
Dokumentumtípus:	Cikk
Megjelent:	2019
Sorozat:	THERAPEUTIC ADVANCES IN GASTROENTEROLOGY 12
doi:	10.1177/1756284819842748
mtmt:	30658417
Online Access:	http://publicatio.bibl.u-szeged.hu/16408

Hasonló tételek

A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease
Szerző: Farkas Klaudia, et al.
Megjelent: (2018)

Outcomes of Patients With Inflammatory Bowel Diseases Switched from Maintenance Therapy with a Biosimilar to Remicade.
Szerző: Iliás Ákos, et al.
Megjelent: (2019)

Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases results from Central European nationwide cohort /
Szerző: Bálint Anita, et al.
Megjelent: (2017)

Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease results of a multicenter survey /
Szerző: Sarlós Patrícia, et al.
Megjelent: (2023)

Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease – a prospective, multicentre study
Szerző: Lontai Livia, et al.
Megjelent: (2022)

Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases a prospective; multicentre; nationwide cohort /
Szerző: Gecse Krisztina Barbara, et al.
Megjelent: (2016)

Outcome of immediate dose optimization of infliximab in inflammatory bowel disease patients
Szerző: Bacsur Péter, et al.
Megjelent: (2022)

Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease
Szerző: Bor Renáta, et al.
Megjelent: (2017)

Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease
Szerző: Pallagi-Kunstár Éva, et al.
Megjelent: (2014)

How do you like the pen? Patients' opinion about switching adalimumab from prefilled syringe to pen in inflammatory bowel disease
Szerző: Szántó Kata, et al.
Megjelent: (2018)

ECCO Guidelines on Inflammatory Bowel Disease and Malignancies
Szerző: Gordon Hannah, et al.
Megjelent: (2023)

Importance of Diet in Inflammatory Bowel Disease – Data from the Patients’ View
Szerző: Molnár Tamás, et al.
Megjelent: (2014)

Long-term consequences of mucosal healing and non-recovery in inflammatory bowel disease
Szerző: Milassin Ágnes Eszter
Megjelent: (2021)

Lupus-like reactions in patients with inflammatory bowel disease
Szerző: Pigniczki Daniella, et al.
Megjelent: (2019)

Iron Deficiency Anemia in Inflammatory Bowel Disease What Do We Know? /
Szerző: Resál Tamás, et al.
Megjelent: (2021)

Inflammatory Bowel Disease and Physical activity a study on the impact of diagnosis on the level of exercise amongst patients with IBD /
Szerző: Gatt K., et al.
Megjelent: (2019)

Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center
Szerző: Farkas Klaudia, et al.
Megjelent: (2015)

Improving disease management of patients with inflammatory bowel disease the potential role of self-concordant health goals /
Szerző: Horvát Barbara, et al.
Megjelent: (2023)

Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn’s disease and ulcerative colitis – experiences from a single center
Szerző: Farkas Klaudia, et al.
Megjelent: (2017)

Spotlight on Transition in Patients With Inflammatory Bowel Disease A Systematic Review /
Szerző: Erős Adrienn, et al.
Megjelent: (2020)

Effects of bowel cleansing on the composition of the gut microbiota in inflammatory bowel disease patients and healthy controls
Szerző: Bacsur Péter, et al.
Megjelent: (2023)

Post-inflammatory polyps burden as a prognostic marker of disease-outcome in patients with inflammatory bowel disease
Szerző: Ellul Pierre, et al.
Megjelent: (2023)

Adverse events associated with management of inflammatory bowel diseases infections and side effects /
Szerző: Bálint Anita
Megjelent: (2015)

The Role of Gut Permeability and Serine-Proteases in the Pathomechanism of Irritable Bowel Syndrome and Inflammatory Bowel Diseases
Szerző: Gecse Krisztina
Megjelent: (2012)

Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis
Szerző: Farkas Klaudia, et al.
Megjelent: (2016)

Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease An ECCO CONFER Multicentre Case Series /
Szerző: Festa Stefano, et al.
Megjelent: (2022)

Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases A European retrospective observational study /
Szerző: Goessens Laurent, et al.
Megjelent: (2021)

Effect of genetical, environmental and clinical factors on the aetiology and natural course of inflammatory bowel disease
Szerző: Molnár Tamás
Megjelent: (2002)

Barriers in inflammatory bowel disease care in Central and Eastern Europe a region-specific analysis /
Szerző: Prokopič Michal, et al.
Megjelent: (2023)

Psychological characteristics of patients with inflammatory bowel disease during the first wave of COVID-19
Szerző: Sánta Anett, et al.
Megjelent: (2023)

Does inflammatory bowel disease have different characteristics according to stage of adolescence?
Szerző: Szántó Kata Judit, et al.
Megjelent: (2021)

Sarcopenia as an independent predictor of the surgical outcomes of patients with inflammatory bowel disease
Szerző: Erős Adrienn, et al.
Megjelent: (2020)

Surgery Due to Inflammatory Bowel Disease During Pregnancy Mothers and Offspring Outcomes From an Ecco Confer Multicentre Case Series (Scar Study) /
Szerző: Chaparro María, et al.
Megjelent: (2022)

Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort
Szerző: Bálint Anita, et al.
Megjelent: (2018)

Specific T-Cell Subsets Can Predict the Efficacy of Anti-TNF Treatment in Inflammatory Bowel Diseases
Szerző: Dulic Sonja, et al.
Megjelent: (2020)

Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics
Szerző: Mandel Michael D., et al.
Megjelent: (2014)

Efficient treatment of a preclinical inflammatory bowel disease model with engineered bacteria
Szerző: Ferenczi Szilamér, et al.
Megjelent: (2021)

Crucial steps for treatment optimization and decision making in inflammatory bowel disease management
Szerző: Szántó Kata Judit
Megjelent: (2023)

Diagnosis and outcome of extranodal primary intestinal lymphoma in inflammatory bowel disease An ECCO CONFER Case Series /
Szerző: Phillips Frank, et al.
Megjelent: (2022)

Biological therapy and surgery rates in inflammatory bowel diseases - Data analysis of almost 1000 patients from a Hungarian tertiary IBD center
Szerző: Szántó Kata, et al.
Megjelent: (2018)